A bipartisan group of House lawmakers introduced the IBOGAINE Act this week, a bill designed to convert President Trump's executive order on psychedelic medicine research into durable federal statute. The legislation targets ibogaine specifically - directing the attorney general to determine within 60 days whether to move the substance from Schedule I to Schedule II under the Controlled Substances Act - while also establishing a broader framework for rescheduling any Schedule I substance that completes Phase 3 clinical trials. The driving force behind it is straightforward: executive orders don't survive administrations, and these lawmakers want the policy to.
For operators in adjacent regulated markets - from cannabis dispensaries monitoring federal scheduling decisions to multi-state operators tracking compliance exposure - the procedural logic here is familiar. Rescheduling processes under the CSA have long frustrated the cannabis industry, and the IBOGAINE Act essentially proposes a faster, more defined track for ibogaine specifically. Whether that model could eventually inform how Congress approaches cannabis rescheduling remains an open question, but the structural parallels are hard to miss. State-licensed cannabis retailers, including those running point-of-sale for Oregon dispensaries, understand better than most how abruptly shifting federal classifications can ripple into compliance requirements, banking access, and operational policy overnight.
Reps. Morgan Luttrell (R-TX), Lou Correa (D-CA), Jack Bergman (R-MI), and Michael McCaul (R-TX) are the bill's primary sponsors. Luttrell and Correa have both spoken publicly about psychedelic therapy's impact on veterans dealing with PTSD and other service-related mental health conditions. Correa and Bergman co-chair the Congressional Psychedelics Advancing Therapies (PATH) Caucus and have been consistent voices pushing to formalize the executive action before a future administration could reverse course. Bergman put it plainly: an executive order lasts only as long as the president who signed it.
What the Bill Actually Does - and Why the Mechanism Matters
The legislation creates a federal definition for ibogaine - encompassing all parts of the Tabernanthe iboga plant and any compound or analog that acts on neuroplasticity, opioid receptors, or serotonergic pathways. That definitional work matters because regulatory frameworks don't function without precise language; vague definitions invite enforcement inconsistency and delay clinical development.
The bill also expands the scope of the federal Right to Try law to explicitly cover Schedule I psychedelics for seriously ill patients, under new special registration requirements it would create. The Drug Enforcement Administration would have to revise production quotas for any substance that gets rescheduled, approved by the FDA, or designated as a breakthrough therapy. A national priority voucher program for psychedelic therapy development would also be codified - and the VA would be required to actually implement access policies rather than simply acknowledge them.
That last piece is not a small thing. Federal agencies receiving broad directives without enforcement mechanisms tend to move slowly. The bill's sponsors seem to understand this; multiple provisions are written with deadlines and mandatory participation language, not permissive guidance.
The Broader Federal Push - and Where the Industry Stands
This bill doesn't exist in a vacuum. HHS Secretary Robert F. Kennedy Jr. has publicly said the administration is working to build a regulatory pathway for psychedelic therapy access, particularly for PTSD and depression, and that he expects rules to move. A Senate committee held a hearing last month on a companion bill that would create a new VA office focused on innovative therapies. Luttrell and several bill co-sponsors are also backing a proposed amendment to the National Defense Authorization Act that would extend a DOD psychedelics research program by six years - cleared for floor action by the House Rules Committee this week.
The momentum is real. What's striking here, though, is how the legislative strategy tracks something cannabis reform advocates have argued for years: agency action without statutory backing is fragile. Rulemaking can be reversed. Enforcement priorities can shift. Only a law actually changes the law. The PATH Caucus members appear to have absorbed that lesson and are moving accordingly.
For cannabis-adjacent businesses watching federal scheduling politics - operators, investors, compliance consultants, and anyone building infrastructure around regulated psychoactive substances - the IBOGAINE Act signals that Congress is at least willing to draft concrete rescheduling timelines and agency mandates when political will aligns. That's a different posture than the cannabis industry has typically encountered on Capitol Hill. Whether it holds through committee, markup, and floor votes is another matter. But the bill is filed, the co-sponsors are bipartisan, and the executive branch is publicly on record as supportive. That combination doesn't show up often.
